To evaluate the effect of estrogen therapy (ET) on endothelial nitric oxide (N O) production and in flow-mediated vasodilation (FMV). Randomized, crossover, d ouble-blind, placebo-con-trolled study. Healthy postmenopa...To evaluate the effect of estrogen therapy (ET) on endothelial nitric oxide (N O) production and in flow-mediated vasodilation (FMV). Randomized, crossover, d ouble-blind, placebo-con-trolled study. Healthy postmenopausal women in an ac ademic research environment. Forty postmenopausal women between 45 and 72 years of age. Women received ET or placebo during two periods of 12 weeks that were se parated by 2 weeks of washout. Flow-mediated vasodilation, nitrite and nitrate, lipid profile, creatinine, and glucose were measured at weeks 12 and 24. Studen t’s t or Wilcoxon tests were used for comparative analyses, and κ.test and lim it analysis determined variability. After placebo treatment, nitrate and nitrite mean concentration was 8.28 ±1.17 mmol/L; it increased to 62.6 ±12.82 mmol/L after ET. Percentage FMV was 18.8 ±2.58 after the placebo period and did not ch ange after ET (20.1 ±1.92) in the whole sample, but in the subgroup (n = 15) of younger women (4550 years of age), percentage FMV increased from 13.6 ±3.6 aft er the placebo period to 22.2 ±3.5 after ET. An increase in plasma concentratio ns of nitrite and nitrate after ET was observed in all the women studied, but th e improvement in FMV was observed only in the younger ones. These age-related d ifferences in FMV in response to ET must be further investigated.展开更多
Aim To establish an RP-HPLC method for the determination of scutellarin in plasma and study its pharmacokinetics in dogs. Methods Scutellarin was given to dogs by intravenous injection and determined by RP-HPLC, the m...Aim To establish an RP-HPLC method for the determination of scutellarin in plasma and study its pharmacokinetics in dogs. Methods Scutellarin was given to dogs by intravenous injection and determined by RP-HPLC, the mean plasma concentration-time curve was plotted and pharmacokinetic parameters were calculated by program 3p87. Resu;ts The concentration-time curve of scutellarin could be fitted to three-compartment model with T1/2 pi, T1/2 α and T1/2 β being 1.05 ± 0.80 min, 6.99 + 2.76 min and 51.61 + 28.78 min, respectively, Vc being 880.1 + 508.3 mL, CL being 189.6 + 53.8 mL@ min- 1, and AUC0-90 and AUC0-∞ being 574.43 + 133.95 μg@ min@ mL - 1 and 599.34 ± 132.00μg@ min@mL- 1, respectively. Conclusion The fact that the concentrations of scutellarin in plasma declined rapidly after the medication suggested that the T1/2 of scutellarin should be taken into account in drug administration and preparation development.展开更多
文摘To evaluate the effect of estrogen therapy (ET) on endothelial nitric oxide (N O) production and in flow-mediated vasodilation (FMV). Randomized, crossover, d ouble-blind, placebo-con-trolled study. Healthy postmenopausal women in an ac ademic research environment. Forty postmenopausal women between 45 and 72 years of age. Women received ET or placebo during two periods of 12 weeks that were se parated by 2 weeks of washout. Flow-mediated vasodilation, nitrite and nitrate, lipid profile, creatinine, and glucose were measured at weeks 12 and 24. Studen t’s t or Wilcoxon tests were used for comparative analyses, and κ.test and lim it analysis determined variability. After placebo treatment, nitrate and nitrite mean concentration was 8.28 ±1.17 mmol/L; it increased to 62.6 ±12.82 mmol/L after ET. Percentage FMV was 18.8 ±2.58 after the placebo period and did not ch ange after ET (20.1 ±1.92) in the whole sample, but in the subgroup (n = 15) of younger women (4550 years of age), percentage FMV increased from 13.6 ±3.6 aft er the placebo period to 22.2 ±3.5 after ET. An increase in plasma concentratio ns of nitrite and nitrate after ET was observed in all the women studied, but th e improvement in FMV was observed only in the younger ones. These age-related d ifferences in FMV in response to ET must be further investigated.
文摘Aim To establish an RP-HPLC method for the determination of scutellarin in plasma and study its pharmacokinetics in dogs. Methods Scutellarin was given to dogs by intravenous injection and determined by RP-HPLC, the mean plasma concentration-time curve was plotted and pharmacokinetic parameters were calculated by program 3p87. Resu;ts The concentration-time curve of scutellarin could be fitted to three-compartment model with T1/2 pi, T1/2 α and T1/2 β being 1.05 ± 0.80 min, 6.99 + 2.76 min and 51.61 + 28.78 min, respectively, Vc being 880.1 + 508.3 mL, CL being 189.6 + 53.8 mL@ min- 1, and AUC0-90 and AUC0-∞ being 574.43 + 133.95 μg@ min@ mL - 1 and 599.34 ± 132.00μg@ min@mL- 1, respectively. Conclusion The fact that the concentrations of scutellarin in plasma declined rapidly after the medication suggested that the T1/2 of scutellarin should be taken into account in drug administration and preparation development.
